
NMRA Stock Forecast & Price Target
NMRA Analyst Ratings
Bulls say
Neumora Therapeutics is well-positioned for success with its diversified pipeline targeting novel mechanisms of action, including its lead program NMRA-140 for treatment-resistant depression. While the company faced a setback with the delay of its NMRA-215 program due to unexpected rat toxicology findings, the management team remains confident in the potential of the drug and has taken necessary steps to address the issue. With multiple near-term catalysts and a strong cash position, Neumora is poised for growth and has the potential for a meaningful re-rating.
Bears say
Neumora Therapeutics is facing a setback as it announces discontinuation of navacaprant development following negative results in its KOASTAL-2/3readout and a 35% reduction in workforce. This lowering of PT from $8 to $5 is largely due to the discontinuation of navacaprant and the potential loss of an effective treatment option with a large market potential of $3B at peak. However, the company still has a good chance of success with its remaining pipeline and a potential upside of $750M in US sales for MDD treatment by 2028. As a result, investors should carefully consider the company's remaining pipeline offerings and long-term growth potential before making any investment decisions.
This aggregate rating is based on analysts' research of Neumora Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
NMRA Analyst Forecast & Price Prediction
Start investing in NMRA
Order type
Buy in
Order amount
Est. shares
0 shares